Cancer

Title
A Study Combining Bendamustine with Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Trial Number
203145
Number of Participants
70
Principal Investigator

Laura Michaelis

M.D., ABIM
Hematology/Oncology
Assistant Professor
Eligibility

To be eligible, adults = 18 years of age must have multiple myeloma that has relapsed or relapsed/refractory disease that is measurable, between one and four prior lines of therapy and a performance status of 2 or better. Please see the protocol for additional requirements.

Purpose

The purpose of this study is to determine the safety, effectiveness and maximum tolerated dose of bendamustine in combination with bortezomib, lenalidomide and dexamethasone.

Enrollment

(708) 327-2316

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.